Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Puma: 3 Key Takeaways for Long-Term Investors
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript
Puma Biotechnology Q3 Earnings Call Highlights
Puma Biotechnology Reports Third Quarter 2026 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Q2 Earnings Call Highlights